In particular, we showed that mir-181ab1 deletion inhibits the oncogenic activity of P12ΔP — one of the strongest NOTCH1 mutants identified in human T-ALL patients [25] — indicating that targeting mir-181ab1 may effectively inhibit the tumorigenic potential of other human Notch1 mutants. Here, NOTCH1 is linked to acute lymphoblastic leukemia.